The efficacy of induction chemotherapy before allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia with multilineage dysplasia (AML-MLD) is unclear. Some patients with AML-MLD have received upfront HCT without prior induction chemotherapy. To compare the transplant outcomes between patients who received upfront HCT and those who received induction chemotherapy followed by allogeneic HCT for AML-MLD, we retrospectively analyzed the Japanese registration data of 1445 adult patients who had received allogeneic HCT between 2007 and 2016. Propensity score matching identified 269 patients in each cohort. There were no significant differences in overall survival between the two groups.
The efficacy of induction chemotherapy before allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia with multilineage dysplasia (AML-MLD) is unclear. Some patients with AML-MLD have received upfront HCT without prior induction chemotherapy. To compare the transplant outcomes between patients who received upfront HCT and those who received induction chemotherapy followed by allogeneic HCT for AML-MLD, we retrospectively analyzed the Japanese registration data of 1445 adult patients who had received allogeneic HCT between 2007 and 2016. Propensity score matching identified 269 patients in each cohort. There were no significant differences in overall survival between the two groups.
The cumulative incidence of leukemia-related mortality was significantly lower in patients who received upfront HCT than those who received induction chemotherapy before HCT. In the subgroup analyses, upfront HCT had a significantly reduced incidence of leukemia-related mortality among patients aged between 60 and 70 years, those with a lower white blood cell count at diagnosis (<3000/μL), and poor cytogenetic risk, and those who received myeloablative conditioning and cord blood transplantation. Our results suggested that induction chemotherapy before HCT did not have any benefits of survival after HCT for AML-MLD. Upfront HCT contributed to the reduced incidence of leukemia-related mortality after HCT. Upfront HCT should be considered for patients with AML-MLD who are eligible for allogeneic HCT. history of MDS and MDS-related cytogenetic abnormalities were significantly associated with poor survival after chemotherapy. 3, 4 Although the prognostic impact of dysplasia in AML is a matter of debate, [3] [4] [5] [6] [7] [8] [9] [10] [11] the presence of dysplasia is a negative independent factor for achieving complete remission (CR) after induction chemotherapy. [4] [5] [6] [7] Several studies demonstrated that approximately 50%-60% achieved CR after induction chemotherapy in patients with AML-MRC or AML with a history of MDS. [4] [5] [6] 12 Even if CR is achieved, the duration of CR is usually short during post-remission chemotherapy, and the number of long-term disease-free survivors remains limited. Moreover, prolonged myelosuppression is the main disadvantage of intensive induction chemotherapy for some of these patients. Prolonged myelosuppression might contribute to infectious and bleeding complications, which are mostly the cause of early mortality and compromising of the eligibility for allogeneic hematopoietic cell transplantation (HCT). Because the efficacy of pre-transplant induction chemotherapy in AML patients with a history of MDS has not been demonstrated, [13] [14] [15] some patients with AML-MLD have received upfront allogeneic HCT without prior induction chemotherapy. 16, 17 Given the lack of randomized clinical trials published to date comparing transplant outcomes of patients who received upfront allogeneic HCT with those who received remission induction chemotherapy followed by allogeneic HCT for AML-MLD, we retrospectively performed a propensity score matched analysis to clarify the impact of upfront HCT for AML-MLD using data from a nationwide Japanese database. patients were eligible for this study ( Figure 1A ). This retrospective study was approved by the institutional review board of the Institute of Medical Science, The University of Tokyo, where this study was carried out.
| INTRODUCTION
Acute
| PATIENTS AND METHODS

| Data collection
| Definitions
The primary objective of this retrospective study was to compare the transplant outcomes of patients who received upfront HCT with those who received induction chemotherapy followed by HCT. Therefore, we defined two treatment groups: the upfront HCT group included patients who underwent allogeneic HCT without remission induction chemotherapy before HCT, whereas the pre-HCT remission induction chemotherapy (ICT) group included patients who received remission induction chemotherapy before HCT. Overall survival (OS) was defined as the time from the date of HCT until death or last observation alive. Leukemia-related mortality was defined as death without remission or after hematological relapse. Non-relapse mortality (NRM) was defined as death without relapse after HCT. Neutrophil engraftment was defined as being achieved on the first of 3 consecutive days when the absolute neutrophil count was higher than 500/μL. The cytogenetic risk was defined according to the National were classified as reduced-intensity conditioning (RIC). 22 The cutoff point of the WBC count at diagnosis was 3000/μL in this study, because physicians may often avoid induction chemotherapy because of the risk of prolonged myelosuppression after induction chemotherapy.
| Propensity score matched analysis
The baseline patient characteristics could have influenced the treatment selection and the transplant outcomes. Therefore, we performed propensity score matched analyses to minimize potential treatment selection bias and eliminate confounding bias in the overall cohort.
Logistic regression was used for the propensity score calculation from the following variables: age, sex, WBC count at diagnosis, cytogenetic risk, prior history of MDS or MDS/MPN, donor source, intensity of conditioning regimen, and year of HCT. A 1:1 matching by propensity score was performed by using the nearest neighbor matching method with a caliper width fixed at 0.2. Propensity score matching was carried out using JMP Pro 13.2.0 (SAS Institute Japan, Co., Ltd., Tokyo, Japan).
| Statistical analysis
To compare differences of variables between the two groups, chisquare test or Fisher's exact test was used for categorical variables, and the Kruskal-Wallis test was used for continuous variables. The probability of OS was calculated using the Kaplan-Meier method, and the log-rank test was used to compare the groups. The probability of leukemia-related mortality, NRM, and neutrophil engraftment were calculated using cumulative incidence curves, taking into account competing risks, and Gray's test was used to compare the groups. The
Cox proportional hazards regression model was used to estimate hazard ratios for overall mortality (inverse of OS), leukemia-related mortality, and NRM. All P-values were two-sided, and the data were analyzed by EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), 23 , a graphical user interface for the R 3.5.0 software program (R Foundation for Statistical Computing, Vienna, Austria).
3 | RESULTS
| Propensity score matching
A total of 1445 patients with AML-MLD, who received the first allogeneic HCT between 2007 and 2016, met the criteria for inclusion.
Of these, 269 patients received upfront HCT, whereas 1176 were treated with remission induction chemotherapy before HCT. Among the overall cohort, the characteristics of sex and cytogenetic risk were comparable between the upfront group and the ICT group, but the proportions of age at HCT, WBC count at diagnosis, prior history of MDS or MDS/MPN, donor source, conditioning regimen, and year of HCT were different. The median time from diagnosis to HCT was 2 months for the upfront HCT group and 4 months for the ICT group (P < .001) ( Table 1 ). In the propensity score matched cohort, 269 patients received upfront HCT, whereas 269 were treated with remission induction chemotherapy before HCT. There were no Cumulative incidence of leukemia-related mortality
Flow chart of patient selection strategy (A). The probability of overall survival and the cumulative incidences of leukemia-related mortality and non-relapse mortality in the overall cohort (B-D) and in the propensity score matched cohort (E-G) significant differences in variables between the two groups, except that the median time from diagnosis to HCT in the upfront HCT group was also shorter than that in the ICT group (P < .001) ( Table 1 ). The c-statistic of propensity score model was 0.79, indicating good discrimination.
| OS, leukemia-related mortality, and NRM
In the overall cohort, the probability of OS was comparable between the upfront HCT group and the ICT group with a median follow-up of 41 months (range, 1-128 months) for survivors (P = .084 by log-rank test, Figure 1B) . The cumulative incidence of leukemia-related mortality was significantly higher in the ICT group compared with that in the upfront HCT group (P = .033 by Gray's test, Figure 1C ). The cumulative incidence of NRM was significantly lower in the ICT group compared with that in the upfront HCT group (P < .001 by Gray's test, Figure 1D ).
With a median follow-up of 37 months (range, 1-128 months) for survivors in the propensity matched cohort, the probability of OS at 3 years was 38% (95% confidence interval [CI]: 32%-44%) for the upfront HCT group and 37% (95% CI: 31%-43%) for the ICT group (P = .732 by log-rank test, Figure 1E ). The cumulative incidence of leukemia-related mortality at 3 years was 33% (95% CI: 27%-39%) for the upfront HCT group and 44% (95% CI: 38%-50%) for the ICT group Abbreviations: HCT, hematopoietic cell transplantation; WBC, white blood cell; MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic/myeloproliferative neoplasm; RBMT/PBSCT, related bone marrow transplantation/peripheral blood stem cell transplantation, UBMT/PBSCT; unrelated bone marrow transplantation/peripheral blood stem cell transplantation; UCBT, unrelated cord blood transplantation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; GVHD, graft-versus-host disease.
(P = .001 by Gray's test, Figure 1F ). The cumulative incidence of NRM at 3 years was 31% (95% CI: 26%-37%) for the upfront HCT group and 25% (95% CI: 20%-30%) for the ICT group (P = .022 by Gray's test, Figure 1G ). However, there was significant difference in the hazard ratio of leukemia-related mortality, but not in NRM, between the two groups ( Figure 2B ,C).
| Engraftment and chimerism
In the overall cohort, the cumulative incidence of neutrophil engraftment was comparable between the upfront HCT group and the ICT group (P = .078 by Gray's test, Supporting Information Figure S1A ). In the propensity score matched cohort, the cumulative incidence of neutrophil engraftment at 30 days was 78% (95% CI: 73%-83%) for the upfront HCT group and 80% (95% CI: 75%-84%) for the ICT group (P = .989 by Gray's test, Supporting Information Figure S1B ).
Among patients who achieved neutrophil engraftment in the propensity score matched cohort, median times to neutrophil engraft- 
| Subgroup analysis in the propensity score matched cohort
In the propensity score matched cohort, we evaluated the overall mortality, leukemia-related mortality, and NRM when stratifying by age, WBC count at diagnosis, cytogenetic risk, history of MDS or MDS/MPN, conditioning regimen, and donor source to identify in which patient group an either better or worse outcome in the upfront HCT group could be observed. The probability of OS did not significantly differ between the two groups among patients within each subgroup (Figure 2A 
Poor cytogenetics
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Cumulative incidence of leukemia-related mortality FIGURE 2 Forest plot for hazard ratios of overall mortality (A), leukemia-related mortality (B), and non-relapse mortality (C) in the propensity score matched cohort. The cumulative incidence of leukemia-related mortality among patients aged between 60 and 70 years (D), those with a lower WBC count at diagnosis (E), and poor cytogenetic risk (F), and those received myeloablative conditioning regimen (G), and cord blood transplantation (H) in the propensity score matched cohort. PSM, propensity score matched; HR, hazard ratio, CI, confidence interval
| Cause of death
Among 538 patients in the propensity matched cohort, 336 patients had died. The cause of death in the upfront HCT group and the ICT group are summarized in Table 2 . The most common cause of death was relapse in the ICT group, whereas it was infection in the upfront HCT group. Although the proportion of infection was closely similar between two groups, organ failure, GVHD, and sinusoidal obstruction syndrome were more common causes of death in the upfront HCT group compared with the ICT group.
| DISCUSSION
Administration of induction chemotherapy before HCT is a complex decision taking into account a patient's age, disease activity, donor availability, and other factors. Because there may be a selection bias between the two groups, a propensity score matching was performed to minimize the potential selection bias and observed confounding bias. Our study clearly demonstrated that remission induction chemotherapy before HCT did not improve survival after HCT. Moreover, the hazard ratio of leukemia-related mortality was significantly lower in patients who received upfront HCT. The subgroup analysis also identified that a significant reduced incidence of leukemia-related mortality after upfront HCT was observed in patients aged between 60 and 70 years, those with a lower WBC count at diagnosis, and poor cytogenetic risk, and those who received MAC and UCBT. These data suggested that induction chemotherapy before HCT did not offer any benefit after HCT.
The main purpose of induction chemotherapy before HCT is to reduce the disease burden, which may contribute to the reduced incidence of relapse after HCT. However, the efficacy of induction chemotherapy has been limited in patients with poor cytogenetic risk and a history of MDS or MDS/MPN, 4,10,12 which were associated with dysplasia in AML. 3, 9 Moreover, several retrospective studies in AML and MDS have shown no significant difference in survival after allogeneic HCT between patients who achieved CR after induction chemotherapy and those who received upfront HCT. [13] [14] [15] Our study also demonstrated that induction chemotherapy did not contribute to survival benefit after HCT for adult patients with AML-MLD, although we did not evaluate the impact of the achievement of CR. Interestingly, upfront HCT contributes to the reduced incidence of leukemia-related mortality after allogeneic HCT, particularly in patients with poor cytogenetic risk and those who received MAC.
Recent studies suggested that the incomplete eradication of minor clones or the existence of resistant clones that acquired additional mutations after induction chemotherapy is the main cause of relapse of AML. 24, 25 Therefore, the increased incidence of leukemia-related mortality after HCT in patients who received induction chemotherapy might be in part due to adverse clonal evolution after induction chemotherapy.
The efficacy of induction chemotherapy before allogeneic HCT might be dependent of the intensity of conditioning regimen.
Although advances in the use of RIC have extended the eligibility of allogeneic HCT to older patients and those with comorbidities, 26 most previous studies in AML and MDS have shown similar survival results between upfront HCT using MAC and induction chemotherapy before HCT. [12] [13] [14] In general, the relapse incidence after allogeneic HCT is usually higher after RIC than after MAC. 27, 28 Therefore, there has been no definitive evidence of a survival benefit of induction chemotherapy before allogeneic HCT using RIC. In a subset analysis, regarding the intensity of conditioning regimen, there were no significant differences in OS, leukemia-related mortality, or NRM between the upfront HCT group and the ICT group in patients who received RIC.
By contrast, upfront HCT contributed to the decreased incidence of leukemia-related mortality after allogeneic HCT in patients who received MAC. These data suggested that induction chemotherapy did not provide any benefit, regardless of the intensity of conditioning regimen. However, further studies are warranted to confirm the impact of induction chemotherapy on the relapse incidence after allogeneic HCT for AML-MLD according to the intensity of conditioning regimen.
Another purpose of induction chemotherapy before allogeneic HCT is to buy time to identify an appropriate donor for allogeneic HCT. Indeed, unrelated BMT/PBSCT (UBMT/PBSCT) usually requires several or more months of donor coordination. In the patients who require urgent allogeneic HCT, alternative donors including unrelated cord blood and haploidentical donor transplantation might also be considered, because the rapid identification of an appropriate donor could favor the applicability of upfront HCT for AML-MLD. In fact, in our study, which is a clinical situation required for urgent HCT, UCBT was the most common donor source in both the overall cohort and propensity score matched cohort. Recent studies have demonstrated similar survival between UBMT, UCBT, and haploidentical donor transplantation in adult AML. [29] [30] [31] [32] [33] Although haploidentical donor transplantation was not included in our study because of their relative infrequency during the study period, upfront HCT from a rapidly available donor, not only cord blood but also a haploidentical family donor, should be considered in adult patients with AML-MLD when HLAcompatible related donors are not available. was not evaluated in our study. Compared with induction chemotherapy, azacitidine has lower rates of CR but has a mild toxicity profile, 37 indicating that azacitidine should be considered a viable alternative to induction chemotherapy as a bridging therapy to allogeneic HCT for older patients and those with comorbidities. Fourth, our study was certainly subject to the selection bias of patients who received allogeneic HCT. For example, patients were precluded from allogeneic HCT due to toxicities, disease progression, or death during an attempt at induction chemotherapy. Moreover, patients in the ICT group, who experienced severe toxicities or organ failure during an attempt at induction chemotherapy, might also be precluded from allogeneic HCT, suggesting that organ failure, sinusoidal obstruction syndrome, and GVHD were more common causes of death in the upfront HCT group in our study. To resolve these limitations, prospective randomized studies evaluating the efficacy of induction chemotherapy on transplant outcomes are needed. Fifth, the proportion of blast and the degree of proliferation of blasts at diagnosis could not be evaluated in our study because of insufficient data. Thus, these parameters of blast might also affect the treatment decision whether induction chemotherapy or HCT should be upfront. Therefore, there might be a group of patients who benefited from the induction chemotherapy before HCT.
In conclusion, this propensity score matched analysis confirmed that induction chemotherapy before allogeneic HCT did not have a survival benefit after allogeneic HCT for adult patients with AML-MLD. Upfront HCT contributed to the reduced incidence of leukemiarelated mortality after allogeneic HCT. Given that patients could not receive HCT because of adverse events and/or disease progression during induction chemotherapy, upfront HCT should be considered for patients with AML-MLD who are eligible for allogeneic HCT. However, the search for a patient group benefited from the induction chemotherapy before HCT is a matter of future investigation.
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